BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 02, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Belinostat: Phase I started

Spectrum began the open-label, dose-escalation, U.S. Phase I BelCHOP trial to evaluate belinostat in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) as first-line treatment in up to 28 patients with PTCL. The trial is intended to establish the recommended Phase III dose for a confirmatory study in the indication. Partner Topotarget said FDA agreed that the...

Read the full 266 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >